| Identification | Back Directory | [Name]
Antofloxacin hydrochloride | [CAS]
873888-67-6 | [Synonyms]
Antofloxacin HCl
Antofloxacin hydrochloride
(S)-Antofloxacin hydrochloride | [Molecular Formula]
C18H22ClFN4O4 | [MDL Number]
MFCD28124371 | [MOL File]
873888-67-6.mol | [Molecular Weight]
412.85 |
| Hazard Information | Back Directory | [Uses]
Antofloxacin hydrochloride is a well tolerate, orally active and broad-spectrum 8-amino-fluoroquinolone with potent antibacterial activities. Antofloxacin hydrochloride shows superior antibacterial activity against gyrA mutation-positive H. pylori strains, especially in Asn87- mutated strains, compared to levofloxacin. Antofloxacin hydrochloride is a weak, reversible inhibitor of CYP1A2 for the research of infections caused by a diverse group of bacterial species[1][2][3]. | [in vivo]
Antofloxacin (2.5~160 mg/kg; s.c.; 24 hours) penetration ratio ranges from 1.22 to 1.54 for the total drug concentrations and is independent of the dose levels[3].
Antofloxacin increases the plasma theophylline concentration, partly by acting as a mechanism based inhibitor of CYP1A2. Antofloxacin inhibits the formation of the three metabolites of theophylline was time-, concentration- and NADPH-dependent, which is characteristic of mechanism-based inhibition[2]. | Animal Model: | Mice (Pharmacokinetic Analysis)[3] | | Dosage: | 2.5~160 mg/kg | | Administration: | S.c.; 24 hours | | Result: | Penetration ratio ranged from 1.22 to 1.54 for the total drug concentrations and was independent of the dose levels. |
| [IC 50]
Quinolone | [References]
[1] He XJ, et al. Efficacy and Safety of Antofloxacin-Based Triple Therapy for Helicobacter pylori Eradication Failure in China [published online ahead of print, 2021 Feb 8]. Dig Dis Sci. 2021;10.1007/s10620-021-06856-z. DOI:10.1007/s10620-021-06856-z
[2] Liu L, et al. Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans. Acta Pharmacol Sin. 2011;32(10):1285-1293. DOI:10.1038/aps.2011.78
[3] Zhou YF, et al. In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2017;61(5):e02691-16. Published 2017 Apr 24. DOI:10.1128/AAC.02691-16 |
|
|